| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Katholieke Universiteit Leuven, Laboratory of Experimental Medicine and Endocrinology (R.B., G.C., L.V., E.v.E., A.V., L.L., C.M.), 3000 Leuven, Belgium; and Massachusetts General Hospital, Endocrine Unit (H.F.L., M.D.), Boston Massachusetts 02114
Correspondence: Address all correspondence and requests for reprints to: Roger Bouillon, Katholieke Universiteit Leuven, Laboratory of Experimental Medicine and Endocrinology, Herestraat 49, O&N 1 bus 902, 3000 Leuven, Belgium. E-mail: Roger.Bouillon{at}med.kuleuven.be
The vitamin D endocrine system is essential for calcium and bone homeostasis. The precise mode of action and the full spectrum of activities of the vitamin D hormone, 1,25-dihydroxyvitamin D [1,25-(OH)2D], can now be better evaluated by critical analysis of mice with engineered deletion of the vitamin D receptor (VDR). Absence of a functional VDR or the key activating enzyme, 25-OHD-1
-hydroxylase (CYP27B1), in mice creates a bone and growth plate phenotype that mimics humans with the same congenital disease or severe vitamin D deficiency. The intestine is the key target for the VDR because high calcium intake, or selective VDR rescue in the intestine, restores a normal bone and growth plate phenotype.
The VDR is nearly ubiquitously expressed, and almost all cells respond to 1,25-(OH)2D exposure; about 3% of the mouse or human genome is regulated, directly and/or indirectly, by the vitamin D endocrine system, suggesting a more widespread function. VDR-deficient mice, but not vitamin D- or 1
-hydroxylase-deficient mice, and man develop total alopecia, indicating that the function of the VDR and its ligand is not fully overlapping. The immune system of VDR- or vitamin D-deficient mice is grossly normal but shows increased sensitivity to autoimmune diseases such as inflammatory bowel disease or type 1 diabetes after exposure to predisposing factors. VDR-deficient mice do not have a spontaneous increase in cancer but are more prone to oncogene- or chemocarcinogen-induced tumors. They also develop high renin hypertension, cardiac hypertrophy, and increased thrombogenicity. Vitamin D deficiency in humans is associated with increased prevalence of diseases, as predicted by the VDR null phenotype. Prospective vitamin D supplementation studies with multiple noncalcemic endpoints are needed to define the benefits of an optimal vitamin D status.
This article has been cited by other articles:
![]() |
G. EELEN, L. VERLINDEN, J. LAUREYS, S. MARCELIS, P. DE CLERCQ, C. MATHIEU, R. BOUILLON, and A. VERSTUYF Antiproliferative and Calcemic Actions of Trans-Decalin CD-Ring Analogs of 1,25-Dihydroxyvitamin D3 Anticancer Res, September 1, 2009; 29(9): 3579 - 3584. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. SEIFERT, W. TILGEN, and J. REICHRATH Expression of 25-Hydroxyvitamin D-1{alpha}-Hydroxylase (1{alpha}OHase, CYP27B1) Splice Variants in HaCaT Keratinocytes and Other Skin Cells: Modulation by Culture Conditions and UV-B Treatment In Vitro Anticancer Res, September 1, 2009; 29(9): 3659 - 3667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. PILZ, A. TOMASCHITZ, B. OBERMAYER-PIETSCH, H. DOBNIG, and T. R. PIEBER Epidemiology of Vitamin D Insufficiency and Cancer Mortality Anticancer Res, September 1, 2009; 29(9): 3699 - 3704. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Agarwal Vitamin D, Proteinuria, Diabetic Nephropathy, and Progression of CKD Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1523 - 1528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Pike, M. B. Meyer, and M. L. Martowicz New Techniques in Transcription Research Extend Our Understanding of the Molecular Actions of the Vitamin D Hormone IBMS BoneKEy, May 1, 2009; 6(5): 169 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Deb, Y. Chen, Z. Zhang, Y. Zhang, F. L. Szeto, K. E. Wong, J. Kong, and Y. C. Li 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1212 - F1218. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |